Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 18, 2024

Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Author(s)Ryan Haumschild, PharmD, MS, MBA, Marwan Fakih, MD , Michael Morse, MD, MHS, FACP

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Episodes in this series

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Tarik Asselah, MD, PhD, screenshot on AJMC branded Q&A background

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

ByLaura Joszt, MA,Tarik Asselah, MD, PhD

June 16th 2026

ChronicLL | Image Credit: © Saiful52-stock.adobe.com

Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

ByMaggie L. Shaw

June 16th 2026

United Therapeutics plans to seek FDA approval for inhaled treprostinil after phase 3 TETON trials demonstrated improved preservation of lung function in IPF. | Image credit: Peakstock_AdobeStock.jpeg

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

BySabrina McCrear

June 16th 2026

Dr Fabio Efficace | Image Credit: GIMEMA Foundation

Patient-Reported QOL Provides Prognostic Insight in AML: Fabio Efficace, PhD, MSc

ByBrooke McCormick,Fabio Efficace, PhD, MSc

June 16th 2026

Investing in the Future: Redesigning Healthcare Infrastructure for CRM Excellence

ByIan J. Neeland, MD

June 16th 2026

Trending on AJMC

Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies

AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose